Antimicrobial resistance (AMR) represents a significant hazard for healthcare workers, particularly those working in high-risk domains such as hospitals dealing with drug-resistant pathogens like Methicillin-resistant Staphylococcus aureus and Vancomycin-resistant Enterococci. Its threat goes beyond merely exposing these workers to these bacteria but permeates the entire healthcare environment. It is often overlooked as a critical issue because of its gradual development, unlike other more acute crises like an Ebola outbreak. Infectious disease expert Dr. Amesh Adalja from the Johns Hopkins Center for Health Security emphasizes the persistent need for strategies to mitigate AMR.
Areas such as labor and delivery units, where prophylactic antibiotics are crucial during caesarean sections, are particularly vulnerable. The rising prevalence of AMR implies more first-line antibiotics, designed to prevent infections, losing their effectiveness, and the subsequent reliance on second-line drugs. This could add to operational costs while decreasing the therapeutic options available.
Antibiotics are not just crucial for active infection management but pivotal in preventing infections during surgeries, facilitating chemotherapy, managing immunocompromised patients, enabling organ transplants, and addressing maternal safety during surgical interventions. AMR brings to the fore a paradox that the Infectious Diseases Society of America refers to as ‘bad bugs and no drugs.’
Resistance to antibiotics is innate to the biology of bacteria, and inaccurate use of these drugs only advances AMR. The persistent prescribing of these drugs due to patient demand or medical uncertainty, even when unnecessary, amplifies this problem, leading to problematic infections like Clostridioides difficile. Dr. Adalja asserts that antibiotics, like all drugs, need judicious application, as their overuse leads to reduced effectiveness over time.
Developing new antibiotics is crucial to counter AMR, yet it is hampered by lack of financial incentive for pharmaceuticals. Hence, policy reforms such as the PASTEUR Act proposing a Netflix-like subscription model are crucial, providing returns to the pharmaceutical companies while ensuring judicious usage of antibiotics.
As part of preventive measures, one needs to enforce proper hand hygiene among healthcare staff, ensure that prescribed antibiotics are medically validated, and recognize prudent antibiotic usage as a public health requirement. The fight against AMR requires a coordinated, sustained effort among policymakers, pharmaceutical companies, healthcare providers, and infection prevention providers. Policy interventions and increasing antibiotic stewardship awareness could hold the key.